Skip to content
NASDAQ · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE · MID CAP

LifeMD, Inc. LFMD

14 fiscal years on record · USD · FY2025 reported · SEC filings only
$194.1M
▲ 25.3% YoY
$14.4M
$6.4M
▼ 60.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

LifeMD provides virtual clinical services as well as prescription and over-the-counter treatments, when medically appropriate. As of December 31, 2025, LifeMD served approximately 328,000 active patient subscribers. The company employed 389 employees as of December 31, 2025, of which 347 were full-time, 5 were part-time, and 37 were temporary. LifeMD operates three consumer healthcare brands focused on largely unaddressed or underserved healthcare needs. The LifeMD brand, a virtual primary care and specialty platform, has served over 679,000 customers and patients to date. Rex MD, the company's men's telehealth platform, has served approximately 691,000 customers and patients since launch. ShapiroMD is a legacy brand offering virtual medical treatment, prescription medications, doctor-formulated over-the-counter products, topical compounded medications, and FDA-approved medical devices for male and female hair loss through the company's telehealth platform. LifeMD, Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc.

Written from the business description in LifeMD, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.

Growth

USD 194.1M
Revenue, FY2025 · full 14-year series below
Revenue $M Net income $M
FY2025 · Revenue 194.1 · Net income 14.4
100.0M200.0M-25.0M-50.0M
201220152018202120242025
Compound annual growth
+17.7%
+39.1%
+66.0%
+0.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +39.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -4.0% · Net 8.0%
-50%-100%-150%
201220182025
ROE
FY2018 · ROE -139.4%
-100%-200%-300%
201220182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -41%.

Cash & shareholders

USD 3.1M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 6.4
10M20M-15M-30M
201220182025
Net buybacks $M Dividends $M
FY2025 · Dividends 3.1 · Net buybacks -8.5
2M3M-3M-6MDividendsNet buybacks
2015201720212022202320242025

USD 3.1M in dividends — 22% of the year's profit went back to shareholders.

Total assetsUSD 70.4M
EquityUSD 23.2M
CashUSD 36.8M
Current ratio1.25×

Equity funds 33% of total assets.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LFMD, 14-year financial record
Metric 20252024202320222021202020192018201720162015201420132012
Revenue $B0.20.20.20.10.10.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.1◌◌◌◌◌−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0−0.0−0.0◌◌◌◌◌◌
Net income $B0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.00.0−0.0−0.0◌◌◌◌◌◌◌◌◌
EPS, diluted $0.25−0.60◌◌◌◌◌◌−0.03−0.030.00−0.02−0.01−0.02
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %22−15−15−7−1—————−17———
ROE %———————−139.4————−162.3−330.1
Shares out B0.050.040.040.030.030.020.050.050.040.040.030.030.030.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: EPS is not tagged before 2012. Five checks were skipped: revenue is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Offices & Clinics of Doctors of Medicine
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2012

Share this section

Download image